| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389550A1 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/17/2001 | CA2389524A1 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| 05/17/2001 | CA2389506A1 Nucleic acid-containing complex |
| 05/17/2001 | CA2389330A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies |
| 05/17/2001 | CA2389326A1 35 human secreted proteins |
| 05/17/2001 | CA2388912A1 6 human secreted proteins |
| 05/17/2001 | CA2388729A1 Imidazopyridine derivatives as phosphodiesterase vii inhibitors |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387959A1 21 human secreted proteins |
| 05/17/2001 | CA2387624A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | CA2382676A1 Prevention of plaque rupture by acat inhibitors |
| 05/17/2001 | CA2361139A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods |
| 05/16/2001 | EP1099701A1 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B |
| 05/16/2001 | EP1099692A1 N,n-substituted cyclic amine derivatives |
| 05/16/2001 | EP1099439A2 Use of apo B secretion/MTP inhibitors |
| 05/16/2001 | EP1098985A1 Genes of the dead box protein family, their expression products and use |
| 05/16/2001 | EP1098978A1 Gbs toxin receptor |
| 05/16/2001 | EP1098974A2 Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| 05/16/2001 | EP1098970A1 Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors |
| 05/16/2001 | EP1098962A2 Diacylglycerol acyl transferase proteins |
| 05/16/2001 | EP1098908A2 Anti-ccr2 antibodies and methods of use therefor |
| 05/16/2001 | EP1098906A1 Peptide analogues of pacap |
| 05/16/2001 | EP1098893A1 Cyclic compounds useful in the treatment of dyslipidemia, atherosclerosis and diabetes, pharmaceutical compositions and preparation process |
| 05/16/2001 | EP1098892A1 Biphenyl derivatives |
| 05/16/2001 | EP1098885A1 Imidazole compounds and their use as adenosine deaminase inhibitors |
| 05/16/2001 | EP1098884A1 Il-8 receptor antagonists |
| 05/16/2001 | EP1098662A2 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| 05/16/2001 | EP1098659A2 Libraries of polyhydroxamates and their analogs |
| 05/16/2001 | EP1098646A1 Stabilized carvedilol injection solution |
| 05/16/2001 | EP1098642A1 Methods for treating conditions modulated by lactosylceramide |
| 05/16/2001 | EP1098639A1 Use of a glucose uptake enhancer for reducing apoptosis |
| 05/16/2001 | EP1098638A1 Use of a glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 05/16/2001 | EP1098634A2 Bioenhanced formulations comprising eprosartan in oral solid dosage form |
| 05/16/2001 | EP0941089B1 Use of anti-microtubule agents for treating or preventing multiple sclerosis |
| 05/16/2001 | EP0882719B1 Arylethenesulfonamide derivatives and drug composition containing the same |
| 05/16/2001 | EP0842165B1 Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents |
| 05/16/2001 | CN1295617A Variants of angiogenic factor vascular endothelial cell growth factor: VEGF |
| 05/16/2001 | CN1295563A 2-arylethyl-(piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists |
| 05/16/2001 | CN1295479A Beta 2-adrenergic receptor agonist |
| 05/16/2001 | CN1295070A Process for prep. of 1-type sodium-hydrogen exchange agent inhibitor |
| 05/16/2001 | CN1294926A Chinese medicine preparation for treating angina pectoris and its dispensation process |
| 05/16/2001 | CN1294911A Substituted nitrobenzene derivative for medicine and other use |
| 05/16/2001 | CN1065861C Phenyl substituted alkenocarboxylic guanidine, preparation method application as medicine or diagnostic agent and medicine containing it |
| 05/16/2001 | CN1065759C Application of tea pigments in preparation of medicine for cor pulmonale |
| 05/15/2001 | US6232449 Persephin and related growth factors |
| 05/15/2001 | US6232438 Angiotensin converting enzyme inhibitors |
| 05/15/2001 | US6232348 Hydroxymethyl derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene as cardiovascular agent |
| 05/15/2001 | US6232345 Cerebral function improving agents |
| 05/15/2001 | US6232335 2,4-Dioxopyrrolidine and 2,4-dioxotetrahydrofan derivatives and medicines containing the same at the active ingredient |
| 05/15/2001 | US6232334 Benzimidazole derivatives, their production and use |
| 05/15/2001 | US6232331 Benzofuroxan derivatives, their therapeutic uses and pharmaceutical compositions |
| 05/15/2001 | US6232329 Tetrahydropyridine-(or 4-hydroxypiperidine) alkylazoles |
| 05/15/2001 | US6232324 Use of pyrazolopyridine compound |
| 05/15/2001 | US6232323 Crystals of piperidine derivatives, intermediates for production of the same, and process for producing the same |
| 05/15/2001 | US6232321 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 05/15/2001 | US6232315 Method for treating inflammatory diseases by administering a thrombin inhibitor |
| 05/15/2001 | US6232314 Arylalkylpiperazine compounds as antioxidants |
| 05/15/2001 | US6232313 Pyridazino quinoline compounds |
| 05/15/2001 | US6232308 Useful for inhibiting bone resorption, treating and preventing osteoporosis, inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, and angiogenesis |
| 05/15/2001 | US6232305 Substituted amino bicyclic-β-lactam penam and cepham derivatives as cysteine protease inhibitors |
| 05/15/2001 | US6232097 Nucleotide sequences coding enzymatic polypeptide; prevent bacterial infection; wound healing agents; for vaccine development |
| 05/15/2001 | US6232071 Tenascin-C nucleic acid ligands |
| 05/15/2001 | US6232064 Fibrosis and atherosclerosis determination |
| 05/15/2001 | US6231884 Plasters for antiischemic agents |
| 05/15/2001 | US6231854 Methioninase formulations and use in diagnostic methods |
| 05/15/2001 | US6231833 Administering to the mammal for treating serotonin system related disorders an effective amount of 2,7-substituted octahydro-1h-pyrido(1,2-a)pyrazine derivative as ligands for serotonin receptor |
| 05/15/2001 | CA2180011C Botulinum toxins for treating sweating |
| 05/15/2001 | CA2034612C Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase |
| 05/15/2001 | CA2009669C Novel n-¬substituted aryl|-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents |
| 05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
| 05/10/2001 | WO2001033218A1 Method for identifying active anti-apoptosis compounds |
| 05/10/2001 | WO2001032926A2 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | WO2001032910A2 27 human secreted proteins |
| 05/10/2001 | WO2001032905A1 Process for producing a product containing antihypertensive tripeptides |
| 05/10/2001 | WO2001032888A2 Human transferase molecules |
| 05/10/2001 | WO2001032877A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 05/10/2001 | WO2001032865A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | WO2001032837A1 19 human secreted proteins |
| 05/10/2001 | WO2001032836A1 Lactobacillus helvetius producing antihypertensive di- and tripeptides |
| 05/10/2001 | WO2001032696A2 Traf family proteins |
| 05/10/2001 | WO2001032695A2 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032680A2 18-nor-steroids as selectively active estrogens |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032676A1 25 human secreted proteins |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032674A1 26 human secreted proteins |
| 05/10/2001 | WO2001032667A1 Ether-type gla-60 analogues |
| 05/10/2001 | WO2001032659A1 Isoquinoline and quinazoline derivatives for the treatment of cns disorders |
| 05/10/2001 | WO2001032658A1 Polyazanaphthalene compound and medicinal use thereof |
| 05/10/2001 | WO2001032654A2 Novel heterocyclic compounds and their use as medicines |
| 05/10/2001 | WO2001032653A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | WO2001032651A1 Quinazoline derivatives as vegf inhibitors |
| 05/10/2001 | WO2001032649A1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032648A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032639A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 05/10/2001 | WO2001032627A1 Process of making substituted pyrazoles |